



Publisher Correction: Stimulation settings in subthalamic nucleus deep brain stimulation for parkinson's disease – a retrospective single-center observational study

Charlotte Schedlich-Teufer¹ · Gregor A. Brandt^{1,2} · Christina van der Linden¹ · Hannah Jergas¹ · Juan Carlos Baldermann^{1,3} · Vasilija Stopic¹ · Gereon R. Fink^{1,4} · Veerle Visser-Vandewalle⁵ · Till A. Dembek¹ · Michael T. Barbe¹ · Jan Niklas Petry-Schmelzer¹

© The Author(s) 2026

Publisher Correction: Neurological Research and Practice (2026) 8:53

<https://doi.org/10.1186/s42466-026-00477-5>

Additionally, Table 3; Fig. 3 are now displayed across the entire width of the page for better readability.

During the incorporation of the proof corrections, some of the rows in Tables 1 and 3 seem to have been inadvertently shifted.

The original article can be found online at <https://doi.org/10.1186/s42466-026-00477-5>.

✉ Charlotte Schedlich-Teufer
charlotte.schedlich-teufer@uk-koeln.de

¹ Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

² Department of Neurology With Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität Zu Berlin, Berlin, Germany

³ Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

⁴ Cognitive Neuroscience, Institute for Neuroscience and Medicine (INM-3), Jülich Research Center, Jülich, Germany

⁵ Department of Stereotactic and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Table 1 in the original article:

Table 1 Patient characteristics in the study cohort

Cohort size [N]	145 (49 female)
Age [years]	63 (± 8.2)
Disease duration [years]	9 (IQR 6–12)
Hoehn and Yahr Stage	3 (IQR 2.5–3)
PD motor subtypes [% , N]	49.0 (71)
- akinetic-rigid	29.6 (31)
- equivalent	21.4 (43)
- tremor-dominant	
LEDD [mg]	1105.2 (± 438.2)
- Preoperative	520 (IQR 300–675)
- 3-MFU	492.5 (IQR 285.6–653.1)
- 6-MFU	466 (IQR 250.4–695.6)
- 12-MFU	
Preoperative UPDRS-III	37.3 (± 11.7)
- Medication Off	19.1 (± 8.2)
- Medication On	
Preoperative levodopa response [%]	46.6 (± 14.5)

IQR=interquartile range, LEDD=levodopa-equivalent daily dose, PD=Parkinson's disease, UPDRS-III=Unified Parkinson's Disease Rating Scale-III

Corrected Table 1:

Table 1 Patient characteristics in the study cohort

Cohort size [N]	145 (49 female)
Age [years]	63 (± 8.2)
Disease duration [years]	9 (IQR 6–12)
Hoehn and Yahr Stage	3 (IQR 2.5–3)
PD motor subtypes [% , N]	49.0 (71)
- akinetic-rigid	29.6 (31)
- equivalent	21.4 (43)
- tremor-dominant	
LEDD [mg]	1105.2 (± 438.2)
- Preoperative	520 (IQR 300–675)
- 3-MFU	492.5 (IQR 285.6–653.1)
- 6-MFU	466 (IQR 250.4–695.6)
- 12-MFU	
Preoperative UPDRS-III	37.3 (± 11.7)
- Medication Off	19.1 (± 8.2)
- Medication On	
Preoperative levodopa response [%]	46.6 (± 14.5)

IQR=interquartile range, LEDD=levodopa-equivalent daily dose, PD=Parkinson's disease, UPDRS-III=Unified Parkinson's Disease Rating Scale-III

Table 3 in the original article:

Table 3 Patient characteristics and clinical outcome data within the subgroups

Patient characteristics	Subgroup BS	Subgroup AS	Subgroup BS to AS
Cohort size [N]	32	59	54
Age [years]	64.3 (± 8.3)	61.8 (± 9.1)	63.6 (± 6.9)
Disease duration [years]	8 (6–14)	9.6 (± 4.1)	9 (6–11)
Hoehn and Yahr Stage	3 (2.5–3.5)	3 (2–3.75)	3 (2.5–3)
PD motor subtypes [% , N]	68.75 (22)	45.8 (27)	40.7 (22)
–akinetic-rigid	18.75 (6)	30.5 (18)	35.2 (19)
–equivalent	12.5 (4)	23.7 (14)	24.1 (13)
–tremor-dominant			
Preoperative UPDRS-III	33.9 (± 11.1)	38.6 (± 12.3)	37.8 (± 11.2)
- Medication Off	16.2 (± 8.2)	20.5 (± 9.1)	19.4 (± 6.8)
- Medication On			
Preoperative levodopa response [%]	54.6 (± 16.1)	47.9 (± 15.0)	48.4 (± 12.4)
LEDD [mg]	1192.2 (± 370.5)	1033.3 (± 472.2)	1132.1 (± 431.7)
- Pre-DBS	579 (362.7–704.1)	416.5 (190.9–624.5)	564.7 (450.9–675)
- 3-MFU	472.4 (± 238.8)	413.2 (± 275.6)	527.5 (340–713.4)
- 6-MFU	488.1 (± 264.4)	400.5 (160.5–696.9)	487.7 (340–742.5)
- 12-MFU			
LEDD Change [%]	55.8 (± 20.9)	57.5 (± 25.6)	44.3 (± 19.9)
- Pre-DBS to 3-MFU	59.9 (± 20.8)	58.9 (± 25.6)	48.3 (± 22.8)
- Pre-DBS to 6-MFU	58 (± 24.3)	56.4 (± 30.2)	52.2 (± 25.8)
- Pre-DBS to 12-MFU			
CPS [μC/s]	10.7 (8.4–14.2)	14.3 (11.3–17.2)	12.3 (10.1–15.6)
- 3-MFU	12.5 (11.1–16.2)	16.1 (12.3–19.5)	15.0 (11.7–17.2)
- 6-MFU	14.4 (12.1–17.8)	18.7 (13.4–21.8)	16.3 (12.0–21.5)
- 12-MFU			

Mean and standard deviation ($\pm$) or median with interquartile range are displayed. AS=advanced stimulation settings, BS=basic stimulation settings, CPS=Charge per second, DBS=deep brain stimulation, LEDD=levodopa-equivalent daily dose, MFU=months follow-up, PD=Parkinson's disease, UPDRS-III=Unified Parkinson's Disease Rating Scale-III

Corrected Table 3:

Table 3 Patient characteristics and clinical outcome data within the subgroups

Patient characteristics	Subgroup BS	Subgroup AS	Subgroup BS to AS
Cohort size [N]	32	59	54
Age [years]	64.3 (± 8.3)	61.8 (± 9.1)	63.6 (± 6.9)
Disease duration [years]	8 (6–14)	9.6 (± 4.1)	9 (6–11)
Hoehn and Yahr Stage	3 (2.5–3.5)	3 (2–3.75)	3 (2.5–3)
PD motor subtypes [% , N]			
- akinetic-rigid	68.75 (22)	45.8 (27)	40.7 (22)
- equivalent	18.75 (6)	30.5 (18)	35.2 (19)
- tremor-dominant	12.5 (4)	23.7 (14)	24.1 (13)
Preoperative UPDRS-III			
- Medication Off	33.9 (± 11.1)	38.6 (± 12.3)	37.8 (± 11.2)
- Medication On	16.2 (± 8.2)	20.5 (± 9.1)	19.4 (± 6.8)
Preoperative levodopa response [%]	54.6 (± 16.1)	47.9 (± 15.0)	48.4 (± 12.4)
LEDD [mg]			
- Pre-DBS	1192.2 (± 370.5)	1033.3 (± 472.2)	1132.1 (± 431.7)
- 3-MFU	579 (362.7–704.1)	416.5 (190.9–624.5)	564.7 (450.9–675)
- 6-MFU	472.4 (± 238.8)	413.2 (± 275.6)	527.5 (340–713.4)
- 12-MFU	488.1 (± 264.4)	400.5 (160.5–696.9)	487.7 (340–742.5)
LEDD Change [%]			
- Pre-DBS to 3-MFU	55.8 (± 20.9)	57.5 (± 25.6)	44.3 (± 19.9)
- Pre-DBS to 6-MFU	59.9 (± 20.8)	58.9 (± 25.6)	48.3 (± 22.8)
- Pre-DBS to 12-MFU	58 (± 24.3)	56.4 (± 30.2)	52.2 (± 25.8)
CPS [μC/s]			
- 3-MFU	10.7 (8.4–14.2)	14.3 (11.3–17.2)	12.3 (10.1–15.6)
- 6-MFU	12.5 (11.1–16.2)	16.1 (12.3–19.5)	15.0 (11.7–17.2)
- 12-MFU	14.4 (12.1–17.8)	18.7 (13.4–21.8)	16.3 (12.0–21.5)

Mean and standard deviation ($\pm$) or median with interquartile range are displayed. AS=advanced stimulation settings, BS=basic stimulation settings, CPS=Charge per second, DBS=deep brain stimulation, LEDD=levodopa-equivalent daily dose, MFU=months follow-up, PD=Parkinson's disease, UPDRS-III=Unified Parkinson's Disease Rating Scale-III

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended

use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.